New gene-immunotherapy combining TRAIL -lymphocytes and EpCAMxCD 3 bispecific antibody for tumor targeting

Purpose: To enhance T-cell responsiveness toward cancer cells, we overexpressed TRAIL in lymphocytes, as this death ligand induces tumor-specific apoptosis. To increase contact time of lymphocytes with tumor cells and thereby of TRAIL with its death receptors, lymphocytes were linked to the CD3 arm...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Groth, Ariane (VerfasserIn) , Salnikov, Alexey V. (VerfasserIn) , Ottinger, Sabine (VerfasserIn) , Gladkich, Jury (VerfasserIn) , Liu, Li (VerfasserIn) , Kallifatidis, Georgios (VerfasserIn) , Salnikova, Olga (VerfasserIn) , Ryschich, Eduard (VerfasserIn) , Giese, Nathalia (VerfasserIn) , Giese, Thomas (VerfasserIn) , Momburg, Frank (VerfasserIn) , Büchler, Markus W. (VerfasserIn) , Moldenhauer, Gerhard (VerfasserIn) , Herr, Ingrid (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: February 2012
In: Clinical cancer research
Year: 2012, Jahrgang: 18, Heft: 4, Pages: 1028-1038
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-11-2767
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1158/1078-0432.CCR-11-2767
Verlag, kostenfrei, Volltext: http://clincancerres.aacrjournals.org/content/18/4/1028
Volltext
Verfasserangaben:Ariane Groth, Alexei V. Salnikov, Sabine Ottinger, Jury Gladkich, Li Liu, Georgios Kallifatidis, Olga Salnikova, Eduard Ryschich, Nathalia Giese, Thomas Giese, Frank Momburg, Markus W. Büchler, Gerhard Moldenhauer and Ingrid Herr

MARC

LEADER 00000caa a2200000 c 4500
001 1576283585
003 DE-627
005 20220814161513.0
007 cr uuu---uuuuu
008 180612s2012 xx |||||o 00| ||eng c
024 7 |a 10.1158/1078-0432.CCR-11-2767  |2 doi 
035 |a (DE-627)1576283585 
035 |a (DE-576)506283585 
035 |a (DE-599)BSZ506283585 
035 |a (OCoLC)1341011536 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Groth, Ariane  |e VerfasserIn  |0 (DE-588)141744057  |0 (DE-627)631177175  |0 (DE-576)325703213  |4 aut 
245 1 0 |a New gene-immunotherapy combining TRAIL -lymphocytes and EpCAMxCD 3 bispecific antibody for tumor targeting  |c Ariane Groth, Alexei V. Salnikov, Sabine Ottinger, Jury Gladkich, Li Liu, Georgios Kallifatidis, Olga Salnikova, Eduard Ryschich, Nathalia Giese, Thomas Giese, Frank Momburg, Markus W. Büchler, Gerhard Moldenhauer and Ingrid Herr 
264 1 |c February 2012 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published first January 6, 2012 
500 |a Gesehen am 12.06.2018 
520 |a Purpose: To enhance T-cell responsiveness toward cancer cells, we overexpressed TRAIL in lymphocytes, as this death ligand induces tumor-specific apoptosis. To increase contact time of lymphocytes with tumor cells and thereby of TRAIL with its death receptors, lymphocytes were linked to the CD3 arm of bispecific antibody EpCAMxCD3, to guide the lymphocytes to tumor cells positive for the cancer stem cell marker EpCAM/ESA. Experimental Design: Lymphocytes were transduced with TRAIL lentivirus and the antitumor effect in presence and absence of EpCAMxCD3 was evaluated in vitro and in xenograft studies using epithelial cell adhesion molecule (EpCAM)-positive pancreatic and prostate cancer cells. Results: Compared with control lymphocytes, TRAIL-lymphocytes increased cytotoxicity and further induced expression of several apoptosis-related molecules. Cotransplantation of TRAIL-lymphocytes and tumor cells in mice or peritumoral injection of TRAIL-lymphocytes in larger xenografts retarded growth and induced apoptosis. Combination of TRAIL-lymphocytes with EpCAMxCD3 potentiated tumor eradication by enhancing antiapoptotic and antiproliferative signaling and by decreasing tumor vasculature. Intratumoral cyst formation was involved and associated with enhanced chemokine secretion and infiltration of mouse macrophages, suggesting contribution of an inflammatory host response. Most importantly, tumorigenicity of pancreatic cancer cells with cancer stem cell features resistant to conventional chemotherapy was strongly reduced. Conclusions: This gene-immunotherapeutic approach may be a new tool to support endogenous immune responses toward cancer even in its advanced stages. Clin Cancer Res; 18(4); 1028-38. ©2012 AACR. 
700 1 |a Salnikov, Alexey V.  |e VerfasserIn  |0 (DE-588)1156427118  |0 (DE-627)1019253800  |0 (DE-576)502180390  |4 aut 
700 1 |a Ottinger, Sabine  |e VerfasserIn  |0 (DE-588)115657031X  |0 (DE-627)1019371455  |0 (DE-576)502264802  |4 aut 
700 1 |a Gladkich, Jury  |e VerfasserIn  |0 (DE-588)1078800960  |0 (DE-627)839492529  |0 (DE-576)45190480X  |4 aut 
700 1 |a Liu, Li  |d 1979-  |e VerfasserIn  |0 (DE-588)1025450906  |0 (DE-627)722293267  |0 (DE-576)370359291  |4 aut 
700 1 |a Kallifatidis, Georgios  |e VerfasserIn  |0 (DE-588)139006540  |0 (DE-627)703178660  |0 (DE-576)309379466  |4 aut 
700 1 |a Salnikova, Olga  |e VerfasserIn  |0 (DE-588)1160963908  |0 (DE-627)1024354326  |0 (DE-576)506289362  |4 aut 
700 1 |a Ryschich, Eduard  |d 1967-  |e VerfasserIn  |0 (DE-588)120246546  |0 (DE-627)696498340  |0 (DE-576)292118090  |4 aut 
700 1 |a Giese, Nathalia  |e VerfasserIn  |0 (DE-588)1033180955  |0 (DE-627)740120018  |0 (DE-576)380769123  |4 aut 
700 1 |a Giese, Thomas  |d 1962-  |e VerfasserIn  |0 (DE-588)143133543  |0 (DE-627)704399075  |0 (DE-576)333724496  |4 aut 
700 1 |a Momburg, Frank  |e VerfasserIn  |0 (DE-588)1104713152  |0 (DE-627)862075041  |0 (DE-576)169249816  |4 aut 
700 1 |a Büchler, Markus W.  |d 1955-  |e VerfasserIn  |0 (DE-588)120893339  |0 (DE-627)080952526  |0 (DE-576)292434146  |4 aut 
700 1 |a Moldenhauer, Gerhard  |e VerfasserIn  |0 (DE-588)1054128634  |0 (DE-627)791055701  |0 (DE-576)410008443  |4 aut 
700 1 |a Herr, Ingrid  |e VerfasserIn  |0 (DE-588)114884242  |0 (DE-627)691233276  |0 (DE-576)168702436  |4 aut 
773 0 8 |i Enthalten in  |t Clinical cancer research  |d Philadelphia, Pa. [u.a.] : AACR, 1995  |g 18(2012), 4, Seite 1028-1038  |h Online-Ressource  |w (DE-627)325489971  |w (DE-600)2036787-9  |w (DE-576)094502234  |x 1557-3265  |7 nnas  |a New gene-immunotherapy combining TRAIL -lymphocytes and EpCAMxCD 3 bispecific antibody for tumor targeting 
773 1 8 |g volume:18  |g year:2012  |g number:4  |g pages:1028-1038  |g extent:11  |a New gene-immunotherapy combining TRAIL -lymphocytes and EpCAMxCD 3 bispecific antibody for tumor targeting 
856 4 0 |u http://dx.doi.org/10.1158/1078-0432.CCR-11-2767  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://clincancerres.aacrjournals.org/content/18/4/1028  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180612 
993 |a Article 
994 |a 2012 
998 |g 114884242  |a Herr, Ingrid  |m 114884242:Herr, Ingrid  |d 910000  |d 910200  |e 910000PH114884242  |e 910200PH114884242  |k 0/910000/  |k 1/910000/910200/  |p 14  |y j 
998 |g 1054128634  |a Moldenhauer, Gerhard  |m 1054128634:Moldenhauer, Gerhard  |d 910000  |e 910000PM1054128634  |k 0/910000/  |p 13 
998 |g 120893339  |a Büchler, Markus W.  |m 120893339:Büchler, Markus W.  |d 910000  |d 910200  |e 910000PB120893339  |e 910200PB120893339  |k 0/910000/  |k 1/910000/910200/  |p 12 
998 |g 1104713152  |a Momburg, Frank  |m 1104713152:Momburg, Frank  |d 910000  |e 910000PM1104713152  |k 0/910000/  |p 11 
998 |g 143133543  |a Giese, Thomas  |m 143133543:Giese, Thomas  |d 910000  |d 911600  |e 910000PG143133543  |e 911600PG143133543  |k 0/910000/  |k 1/910000/911600/  |p 10 
998 |g 1033180955  |a Giese, Nathalia  |m 1033180955:Giese, Nathalia  |d 910000  |d 910200  |e 910000PG1033180955  |e 910200PG1033180955  |k 0/910000/  |k 1/910000/910200/  |p 9 
998 |g 120246546  |a Ryschich, Eduard  |m 120246546:Ryschich, Eduard  |d 910000  |d 910200  |e 910000PR120246546  |e 910200PR120246546  |k 0/910000/  |k 1/910000/910200/  |p 8 
998 |g 1160963908  |a Salnikova, Olga  |m 1160963908:Salnikova, Olga  |d 910000  |d 910200  |e 910000PS1160963908  |e 910200PS1160963908  |k 0/910000/  |k 1/910000/910200/  |p 7 
998 |g 139006540  |a Kallifatidis, Georgios  |m 139006540:Kallifatidis, Georgios  |d 140000  |e 140000PK139006540  |k 0/140000/  |p 6 
998 |g 1025450906  |a Liu, Li  |m 1025450906:Liu, Li  |d 50000  |e 50000PL1025450906  |k 0/50000/  |p 5 
998 |g 1078800960  |a Gladkich, Jury  |m 1078800960:Gladkich, Jury  |p 4 
998 |g 115657031X  |a Ottinger, Sabine  |m 115657031X:Ottinger, Sabine  |d 910000  |d 910100  |e 910000PO115657031X  |e 910100PO115657031X  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 1156427118  |a Salnikov, Alexey V.  |m 1156427118:Salnikov, Alexey V.  |d 910000  |d 910200  |e 910000PS1156427118  |e 910200PS1156427118  |k 0/910000/  |k 1/910000/910200/  |p 2 
998 |g 141744057  |a Groth, Ariane  |m 141744057:Groth, Ariane  |d 910000  |d 910200  |e 910000PG141744057  |e 910200PG141744057  |k 0/910000/  |k 1/910000/910200/  |p 1  |x j 
999 |a KXP-PPN1576283585  |e 3012538364 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"325489971","name":{"displayForm":["American Association for Cancer Research"]},"language":["eng"],"part":{"volume":"18","text":"18(2012), 4, Seite 1028-1038","issue":"4","year":"2012","pages":"1028-1038","extent":"11"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2036787-9"],"eki":["325489971"],"issn":["1557-3265"]},"origin":[{"publisher":"AACR","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995","dateIssuedDisp":"1995-"}],"corporate":[{"display":"American Association for Cancer Research","role":"isb"}],"disp":"New gene-immunotherapy combining TRAIL -lymphocytes and EpCAMxCD 3 bispecific antibody for tumor targetingClinical cancer research","note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1995 -"],"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}]}],"physDesc":[{"extent":"11 S."}],"title":[{"title":"New gene-immunotherapy combining TRAIL -lymphocytes and EpCAMxCD 3 bispecific antibody for tumor targeting","title_sort":"New gene-immunotherapy combining TRAIL -lymphocytes and EpCAMxCD 3 bispecific antibody for tumor targeting"}],"recId":"1576283585","id":{"doi":["10.1158/1078-0432.CCR-11-2767"],"eki":["1576283585"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Ariane Groth, Alexei V. Salnikov, Sabine Ottinger, Jury Gladkich, Li Liu, Georgios Kallifatidis, Olga Salnikova, Eduard Ryschich, Nathalia Giese, Thomas Giese, Frank Momburg, Markus W. Büchler, Gerhard Moldenhauer and Ingrid Herr"]},"origin":[{"dateIssuedDisp":"February 2012","dateIssuedKey":"2012"}],"note":["Published first January 6, 2012","Gesehen am 12.06.2018"],"language":["eng"],"person":[{"given":"Ariane","role":"aut","family":"Groth","display":"Groth, Ariane"},{"given":"Alexey V.","display":"Salnikov, Alexey V.","role":"aut","family":"Salnikov"},{"display":"Ottinger, Sabine","family":"Ottinger","role":"aut","given":"Sabine"},{"given":"Jury","role":"aut","family":"Gladkich","display":"Gladkich, Jury"},{"role":"aut","family":"Liu","display":"Liu, Li","given":"Li"},{"display":"Kallifatidis, Georgios","family":"Kallifatidis","role":"aut","given":"Georgios"},{"family":"Salnikova","role":"aut","display":"Salnikova, Olga","given":"Olga"},{"given":"Eduard","role":"aut","family":"Ryschich","display":"Ryschich, Eduard"},{"family":"Giese","role":"aut","display":"Giese, Nathalia","given":"Nathalia"},{"family":"Giese","role":"aut","display":"Giese, Thomas","given":"Thomas"},{"display":"Momburg, Frank","role":"aut","family":"Momburg","given":"Frank"},{"family":"Büchler","role":"aut","display":"Büchler, Markus W.","given":"Markus W."},{"role":"aut","family":"Moldenhauer","display":"Moldenhauer, Gerhard","given":"Gerhard"},{"given":"Ingrid","display":"Herr, Ingrid","role":"aut","family":"Herr"}]} 
SRT |a GROTHARIANNEWGENEIMM2012